Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome.
Natural killer (NK)3 cells are large granular lymphocytes that appear to play a significant role in the host's defense against viral infection. We performed an extensive phenotypic and functional characterization of NK cells on 41 patients with the chronic fatigue syndrome (CFS), or "chronic active Epstein-Barr virus infection" syndrome, and on 23 age- and sex-matched asymptomatic control subjects in an attempt to further characterize this illness. These studies demonstrated that a majority of patients with CFS have low numbers of NKH1+T3- lymphocytes, a population that represents the great majority of NK cells in normal individuals. CFS patients had normal numbers of NKH1+T3+ lymphocytes, a population that represents a relatively small fraction of NK cells in normal individuals. When tested for cytotoxicity against a variety of different target cells, patients with CFS consistently demonstrated low levels of killing. After activation of cytolytic activity with recombinant interleukin 2, patients were able to display increased killing against K562 but most patients remained unable to lyse Epstein-Barr virus-infected B cell targets. Additional cytotoxicity experiments were carried out utilizing anti-T3 monoclonal antibody to block killing by NKH1+T3+ cells. These experiments indicated that the NK cell that appears to be responsible for much of the functional activity remaining in patients with CFS belongs to the NKH1+T3+ subset, which under normal circumstances represents only approximately 20% of the NK cell population.
Caligiuri
M
M
Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115.
Murray
C
C
Buchwald
D
D
Levine
H
H
Cheney
P
P
Peterson
D
D
Komaroff
A L
AL
Ritz
J
J
D000914:Antibodies, Viral / Q000032:analysis; D002140:California; D002908:Chronic Disease; D004198:Disease Susceptibility; D005221:Fatigue / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D006566:Herpesviridae Infections / Q000276:immunology* / Q000473:pathology; D004854:Herpesvirus 4, Human / Q000472:pathogenicity*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000209:etiology / Q000276:immunology*; D007694:Killer Cells, Natural / Q000145:classification / Q000276:immunology* / Q000473:pathology; D008404:Massachusetts; D010641:Phenotype; D014775:Virus Activation; D014777:Virus Diseases / Q000276:immunology
D000914:Antibodies, Viral